期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 29, 期 7, 页码 925-933出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.27.2369
关键词
-
类别
资金
- National Institutes of Health [R01-CA098951, P50-CA083638, R01-CA112162]
- Ovarian Cancer Immunotherapy Initiative
In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing. J Clin Oncol 29: 925-933. (C) 2010 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据